Flavoxate
Urispas (flavoxate) is a small molecule pharmaceutical. Flavoxate was first approved as Urispas on 1982-01-01. It is used to treat dysuria, nocturia, and urinary incontinence in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Flavoxate hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| URISPAS | Johnson & Johnson | N-016769 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| flavoxate hydrochloride | ANDA | 2022-02-08 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| dysuria | EFO_0003901 | D053159 | R30 |
| nocturia | — | D053158 | R35.1 |
| urinary incontinence | HP_0000020 | D014549 | R32 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
226 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | 3 | 9 | 6 | 10 | 6 | 31 |
| Afibrinogenemia | D000347 | D68.2 | 1 | 5 | 4 | 2 | 1 | 10 | |
| Wounds and injuries | D014947 | T14.8 | 2 | 5 | 3 | 1 | — | 9 | |
| Hemostasis | D006487 | 1 | 1 | 1 | 3 | 1 | 6 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | 2 | 1 | 2 | 5 |
| Anastomotic leak | D057868 | — | 1 | 1 | 2 | 1 | 5 | ||
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | 2 | — | 2 | — | 4 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 2 | — | 1 | — | 3 |
| Lymphocele | D008210 | — | — | 2 | 1 | — | 3 | ||
| Cardiac surgical procedures | D006348 | — | 1 | — | 1 | 1 | 3 |
Show 17 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pterygium | D011625 | H11.0 | 2 | 1 | 2 | — | 5 | 9 | |
| Surgical blood loss | D016063 | — | — | 2 | — | 3 | 5 | ||
| Postoperative hemorrhage | D019106 | — | 2 | 1 | — | 1 | 4 | ||
| Replacement arthroplasty knee | D019645 | — | — | 2 | — | 2 | 4 | ||
| Cerebrospinal fluid leak | D065634 | G96.0 | — | 1 | 2 | — | — | 3 | |
| Rectal fistula | D012003 | HP_0010447 | K60.3 | — | — | 3 | — | — | 3 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | 1 | — | 2 | 3 |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | — | 1 | 2 |
| Hemorrhagic shock | D012771 | — | — | 2 | — | — | 2 | ||
| Tympanic membrane perforation | D018058 | H72 | — | — | 1 | — | 1 | 2 |
Show 28 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | — | 1 | — | — | 2 | 3 |
| Multiple trauma | D009104 | T07 | 1 | 1 | — | — | 2 | 3 | |
| Coronary artery disease | D003324 | I25.1 | — | 2 | — | — | — | 2 | |
| Seroma | D049291 | — | 1 | — | — | 1 | 2 | ||
| Chronic periodontitis | D055113 | EFO_0006343 | K05.3 | 2 | 1 | — | — | — | 2 |
| Rotator cuff injuries | D000070636 | M75.1 | — | 2 | — | — | — | 2 | |
| Burns | D002056 | T30.0 | 1 | 1 | — | — | 1 | 2 | |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | 1 | |
| Gallstones | D042882 | EFO_0004210 | — | 1 | — | — | — | 1 | |
| Pathologic processes | D010335 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal ulcer | D003320 | H16.0 | 1 | — | — | — | 1 | 2 | |
| Intraabdominal infections | D059413 | 1 | — | — | — | — | 1 | ||
| Intestinal fistula | D007412 | K63.2 | 1 | — | — | — | — | 1 | |
| Tendinopathy | D052256 | EFO_1001434 | M77.9 | 1 | — | — | — | — | 1 |
| Periodontal diseases | D010510 | K05.6 | 1 | — | — | — | — | 1 | |
| Periodontal pocket | D010514 | EFO_1001393 | 1 | — | — | — | — | 1 | |
| Periodontal attachment loss | D017622 | 1 | — | — | — | — | 1 | ||
| Abdominal hernia | D046449 | K46 | 1 | — | — | — | — | 1 | |
| Ventral hernia | D006555 | EFO_1001866 | K43 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 2 | 2 |
| Cataract | D002386 | EFO_0001059 | H26.9 | — | — | — | — | 1 | 1 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 1 | 1 |
| Cerebral hemorrhage | D002543 | — | — | — | — | 1 | 1 | ||
| Stomach diseases | D013272 | — | — | — | — | 1 | 1 | ||
| Esophageal diseases | D004935 | EFO_0009544 | K22.9 | — | — | — | — | 1 | 1 |
| Ovarian cysts | D010048 | HP_0000138 | N83.1 | — | — | — | — | 1 | 1 |
| Patent ductus arteriosus | D004374 | HP_0001643 | Q25.0 | — | — | — | — | 1 | 1 |
Show 21 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FLAVOXATE |
| INN | flavoxate |
| Description | Flavoxate is a carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol. It has a role as a parasympatholytic, a muscarinic antagonist and an antispasmodic drug. It is a member of piperidines, a member of flavones, a carboxylic ester and a tertiary amino compound. It is functionally related to a 3-methylflavone-8-carboxylic acid and a 2-(piperidin-1-yl)ethanol. It is a conjugate base of a flavoxate(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O |
Identifiers
| PDB | — |
| CAS-ID | 15301-69-6 |
| RxCUI | 4440 |
| ChEMBL ID | CHEMBL1493 |
| ChEBI ID | 5088 |
| PubChem CID | 3354 |
| DrugBank | DB01148 |
| UNII ID | 3E74Y80MEY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 260 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
639 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more